- 260
- 39 154
HealthTree Foundation for Blood Cancers
United States
เข้าร่วมเมื่อ 27 เม.ย. 2022
HealthTree Foundation empowers patients with blood cancers at each step of their disease journey - from diagnosis, through education, care and on to a cure. The HealthTree Foundation does this through three areas of support; simplified patient education, support research driven by patient needs, and the use of data to solve patient and research problems.
Golcadomide ± Rituximab in Relapsed/Refractory Large B-cell Lymphoma | Julio Chavez, MD, MS | #ASH24
New research for DLBCL with Golcadomide and Rituximab combinations presented by Dr. Julio Chavez, MD, MS at ASH 2024.
ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b
ASH Abstract: ashpublications.org/blood/article/144/Supplement%201/869/531072/Longer-Follow-up-of-Golcadomide-GOLCA-a-Cereblon
#ASH24 #DLBCL #lymsm
Follow HealthTree: linktr.ee/HealthTreeUniversity
ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b
ASH Abstract: ashpublications.org/blood/article/144/Supplement%201/869/531072/Longer-Follow-up-of-Golcadomide-GOLCA-a-Cereblon
#ASH24 #DLBCL #lymsm
Follow HealthTree: linktr.ee/HealthTreeUniversity
มุมมอง: 20
วีดีโอ
Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL | Julio Chavez, MD, MS | #ASH24
มุมมอง 1419 ชั่วโมงที่ผ่านมา
Promising new research on Mosunetuzumab and Polatuzumab Vedotin combinations presented by Dr. Julio Chavez, MD, MS at ASH 2024. ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: ash.confex.com/ash/2024/webprogram/Paper194581.html #ASH24 #DLBCL #lymsm Follow HealthTree: linktr.ee/HealthTreeUniversity
The Iron Survivor: Chronic Lymphocytic Leukemia Patient Spotlight Pratik Desai
มุมมอง 2519 ชั่วโมงที่ผ่านมา
A special webinar with Pratik Desai, a father, husband, Ironman athlete, and CLL community member, sharing his inspiring journey. Recorded on January 17th, 2025 as part of the Chronic Lymphocytic Leukemia Group in the Educational Webinar Program by HealthTree with Pratik Desai. The HealthTree Foundation brings information from the experts to the patients! Learn more at healthtree.org/ Donate to...
Factors Influencing Enrollment in Hematologic Cancer Trials (2008-2023) | Rupayan Kundu, MD | #ASH24
มุมมอง 29วันที่ผ่านมา
Dr. Rupayan Kundu from the Cleveland Clinic Foundation shares data from a long term study involving enrollment rate in clinical trials. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: ashpublications.org/blood/article/144/Supplement 1/5059/534184/Analysis-of-Factors-Influencing-Enrollment-Success Follow HealthTree: linktr.ee/HealthTreeUniv...
Barriers to Stem Cell Transplant in #AML: NC Cohort Insights | Michele Sainvil, MD | #ASH24
มุมมอง 13วันที่ผ่านมา
Dr. Michele Sainvil from Duke University Medical Center shares new insights into sociodemographic barriers for stem cell transplants. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: ashpublications.org/blood/article/144/Supplement 1/2295/531170/Understanding-Sociodemographic-Barriers-in #ASH24 #aml #leusm Follow HealthTree: linktr.ee/Healt...
Fresh Start 2025: Manage Nutrition Side Effects from AML Care with Science-Based Strategies
มุมมอง 3214 วันที่ผ่านมา
Francesca Castro, MS, RD will provide practical, science-backed strategies to help you manage nutrition-related side effects of AML treatment and transplant. Recorded on January 9th, 2025 as part of the Acute Myeloid Leukemia Group in the Educational Webinar Program by HealthTree with Francesca Castro, MS, RD and Peter Adintori, MS, RD-AP, CSO, CDN, CNSC. The HealthTree Foundation brings inform...
TP53-Mutated AML & MDS: Why Clinical Trials Are Your Best Option | Dan Link, MD | #ASH24
มุมมอง 5814 วันที่ผ่านมา
Learn what patients and their medical team can do when managing TP53 AML. Link to ASH playlist: healthtree.org/blood-cancer/university/mod ules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Handling Bad News: How to Best Manage TP53 Myeloid Disease #ASH24 #AML #leusm Follow HealthTree: linktr.ee/HealthTreeUniversity
Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24
มุมมอง 4114 วันที่ผ่านมา
Learn about the early findings in this clinical trial about menin inhibitors and how they may change the way AML is treated. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Ziftomenib Combined with Intensive Induction (7 3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007 #ASH24 #AML #leu...
Promising Early Results from Menin Inhibitors for Treating AML | Harry Erba, MD | #ASH24
มุมมอง 2214 วันที่ผ่านมา
Dr. Henry Erba talks early results from clinical trials about menin inhibitors, and how they are being used in treating AML. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b #ASH24 #AML #leusm Follow HealthTree: linktr.ee/HealthTreeUniversity
Promising Results for CAR-T Cell therapy for Follicular Lymphoma | Matthew Frank, MD, PhD | #ASH24
มุมมอง 3114 วันที่ผ่านมา
Dr Matthew Frank discusses the promising results of a phase 1 CAR-T study for follicular lymphoma. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma #ASH24 #FollicularLymphoma #lymsm Follow HealthTree: linkt...
A Conversation about the Phase III SENTRY Trial for Myelofibrosis with Dr. John Mascarenhas
มุมมอง 7วันที่ผ่านมา
In this HealthTree for Myelofibrosis podcast episode, we spoke with Dr. John Mascarenhas about the SENTRY Trial (NTC04562389). Dr. Mascarenhas is the principal investigator on this global, phase III clinical trial.
ACA Changes and Medicaid Expansion: What Blood Cancer Patients Need to Know and How to Stay Prepared
มุมมอง 7721 วันที่ผ่านมา
Join our webinar for blood cancer patients on ACA changes, Medicaid expansion, and strategies to safeguard healthcare with expert Diahanna Vallentine. Recorded on January 7th, 2024 as part of the Financial Education Group in the Educational Webinar Program by HealthTree with Diahanna Vallentine. The HealthTree Foundation brings information from the experts to the patients! Learn more at healtht...
Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24
มุมมอง 3421 วันที่ผ่านมา
Dr Yasmina Serroukh discusses a study looking at outcomes with stem cell transplantation for patients with follicular lymphoma. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and M...
Odronextamab as First-Line Therapy in Follicular Lymphoma | Rueme Birhiray, MD | #ASH24
มุมมอง 3021 วันที่ผ่านมา
Dr Rueme Birhiray discusses a new class of drug, bispecific antibodies, for patients with follicular lymphoma, specifically studies looking at odronextamab. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the ...
Phase 3 Asciminib Tolerability Trial , ASC4FIRST, for Patients with CML | David Andorsky |#ASH2024
มุมมอง 1221 วันที่ผ่านมา
Dr David Andorsky discusses the ASC4FIRST trial looking at the safety and tolerability of asciminib. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chroni...
The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024
มุมมอง 1721 วันที่ผ่านมา
The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024
Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24
มุมมอง 1121 วันที่ผ่านมา
Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24
Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24
มุมมอง 1421 วันที่ผ่านมา
Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24
BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024
มุมมอง 3521 วันที่ผ่านมา
BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024
Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24
มุมมอง 4721 วันที่ผ่านมา
Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24
Quality of Life Dispairities for Patients with MDS | Somedeb Ball, MBBS | #ASH24
มุมมอง 1821 วันที่ผ่านมา
Quality of Life Dispairities for Patients with MDS | Somedeb Ball, MBBS | #ASH24
Importance of Support for Caregivers of Transfusion Dependent Patients | Maria Diez-Campelo | #ASH24
มุมมอง 1021 วันที่ผ่านมา
Importance of Support for Caregivers of Transfusion Dependent Patients | Maria Diez-Campelo | #ASH24
Benefits of Thorough Evaluations Before Starting AML Treatment | Samuel Yates, MD, MS | #ASH24
มุมมอง 1621 วันที่ผ่านมา
Benefits of Thorough Evaluations Before Starting AML Treatment | Samuel Yates, MD, MS | #ASH24
Impact of Transplant Timing in MDS Treatment | Benajmin Rolles, MD | #ASH24
มุมมอง 1221 วันที่ผ่านมา
Impact of Transplant Timing in MDS Treatment | Benajmin Rolles, MD | #ASH24
How Self-Rated Health Impacts Patient Outcomes| Nora Balas, PhD | #ASH24
มุมมอง 4421 วันที่ผ่านมา
How Self-Rated Health Impacts Patient Outcomes| Nora Balas, PhD | #ASH24
Examining 3 Key Studies on Treatments for AML and ALL | Jayastu Senapati, MD, MBBS | #ASH24
มุมมอง 2621 วันที่ผ่านมา
Examining 3 Key Studies on Treatments for AML and ALL | Jayastu Senapati, MD, MBBS | #ASH24
Inpatient or Outpatient Consolidation Therapy: Which is Better?| Leora Boussi, MD | #ASH24
มุมมอง 1321 วันที่ผ่านมา
Inpatient or Outpatient Consolidation Therapy: Which is Better?| Leora Boussi, MD | #ASH24
Racial Disparities in Youth and Young Adults with AML | Erin Feliciano, MD | #ASH24
มุมมอง 3621 วันที่ผ่านมา
Racial Disparities in Youth and Young Adults with AML | Erin Feliciano, MD | #ASH24
AML: New Strategies For Preventing Graft vs Host Disease | Giorgia Battipaglia, MD | #ASH24
มุมมอง 1721 วันที่ผ่านมา
AML: New Strategies For Preventing Graft vs Host Disease | Giorgia Battipaglia, MD | #ASH24
Revumenib: New Approved Drug for Relapsed/Refractory Acute Leukemia Patients | Eytan Stein | #ASH24
มุมมอง 2621 วันที่ผ่านมา
Revumenib: New Approved Drug for Relapsed/Refractory Acute Leukemia Patients | Eytan Stein | #ASH24
I love this guy! Gr8 Doctor!
My doctor tried a kind of immuneo therapy on mine three years ago but it didn’t do anything.
Plz any cure for colon cancer to many children dying from thet plz help them the are children
Sir pls do somthing and help the peopel i thing FDA has the cancer cure plz help children
Thank you so much for posting this Dr. Joanna Rhodes . It gives so much relevant information
Hi, hope u r doing good. I was diagnosed with cancer{(aml [inv16(16:16)} and doctor advised for bmt, so i did(haplo). Now, biopsy report is normal but mrd is positive with 227 aml copies. What should i do now?
Clearest insight I have found thank you
We're so glad you found this recording helpful. We have a variety of additional follicular lymphoma resources you can access by visiting our website: www.healthtree.org/follicular-lymphoma/community
Very nice!
Thanks for the forecast! Could you help me with something unrelated: I have a SafePal wallet with USDT, and I have the seed phrase. (behave today finger ski upon boy assault summer exhaust beauty stereo over). What's the best way to send them to Binance?
you go then!
Sir, what to do for hypo plastic MDS del 20q?
😊
Wise ... live each day as if it is your first ... and never give up hope!
Thank you for this advice Dr Chavez.
Hi Doctor, do you treat autoimmune hemolytic Anemia?
That is very promising,if the drug is 10 times stronger than venetoclax maybe that combination will offer a cure to some patients.
Absolutely terrific presentation by Dr Thompson! As a CLL-Small Cell B, I have just started Rx with Brukinsa for very bulky Axillary nodes. On the lookout for potential infections!
What will be the best therapy for MDS del 20q?.please suggest me
My momma was saved by this very treatment! Thank you Dr.Strati and your team! We are forever grateful.
This is amazing. We're so glad to hear a little bit about your mom's story!
*Promo sm*
Hope is allways available... God bless your efforts...
My dad is 67, turns 68 Feb 5th. He has non-small cell lung cancer and AML. He decided to do no treatment, and he has been told he has less than 6 months. He's refusing hospice, and as his daughter that lives in the home with him, all the responsibility is put on me. He also doesn't want to believe his pain is from the cancer. He believes he might not die or is hopeful he won't. This has been very hard to deal with. Any advice would be helpful.
Thank you for watching! I'm sorry to hear about your father's diagnosis. Being a caregiver in this situation is a big responsibility and can feel very overwhelming. We have several articles/events on caregiving that might be helpful. Reach out to me at mary@healthtree.org and I can share those resources with you!
@@HealthTreeforbloodcancers Thank you I will.
Exciting.
So amazing!!!!!
Well done, Dr. Mannis. Thanks.
We are glad you enjoyed this presentation!
Thank you for making the video
found out I have AML FTL3 in july and I go for a BMT after thanksgiving. I am scared to death